LOXL2 and breast cancer: By taking advantage of the CPTAC proteomics dataset (Krug et al, 2020), we stratified breast cancer samples into different breast cancer subtypes and observed that LOXL2 protein levels were significantly increased in each of them, whereas BRD4 only showed a mild increase in TNBC (Fig 1B).